RET, ROS1 and ALK fusions in lung cancer.
Nat Med
; 18(3): 378-81, 2012 Feb 12.
Article
em En
| MEDLINE
| ID: mdl-22327623
ABSTRACT
Through an integrated molecular- and histopathology-based screening system, we performed a screening for fusions of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1, receptor tyrosine kinase (ROS1) in 1,529 lung cancers and identified 44 ALK-fusion-positive and 13 ROS1-fusion-positive adenocarcinomas, including for unidentified fusion partners for ROS1. In addition, we discovered previously unidentified kinase fusions that may be promising for molecular-targeted therapy, kinesin family member 5B (KIF5B)-ret proto-oncogene (RET) and coiled-coil domain containing 6 (CCDC6)-RET, in 14 adenocarcinomas. A multivariate analysis of 1,116 adenocarcinomas containing these 71 kinase-fusion-positive adenocarcinomas identified four independent factors that are indicators of poor prognosis age ≥ 50 years, male sex, high pathological stage and negative kinase-fusion status.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Proteínas Tirosina Quinases
/
Adenocarcinoma
/
Proteínas de Fusão Oncogênica
/
Proteínas Proto-Oncogênicas
/
Receptores Proteína Tirosina Quinases
/
Proteínas Proto-Oncogênicas c-ret
/
Neoplasias Pulmonares
Tipo de estudo:
Prognostic_studies
Limite:
Adult
/
Aged
/
Aged80
/
Animals
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Nat Med
Ano de publicação:
2012
Tipo de documento:
Article